Please login to the form below

Not currently logged in
Email:
Password:

Daiichi Sankyo begins sharing clinical trial data online

Joins the likes of GSK, Lilly, UCB and Astellas in opening up its records

Daiichi Sankyo

Daiichi Sankyo has joined many of its industry peers in their transparency efforts by signing up to a portal that provides anonymised patient-level data on request to qualified researchers.

The Japanese pharma company said requests can now be submitted via the Clinical Study Data Request website for data from its trials for medicines that are approved in the EU and US.

Mahmoud Ghazzi, global head of development for Daiichi Sankyo, said: "Sharing clinical data from trials sponsored by Daiichi Sankyo with qualified researchers helps foster additional scientific insights and provides a mechanism for further understanding of our medicines, which ultimately is a benefit to patient healthcare.”

The company said it will provide data for medicines and indications approved on or after 1 January 2014, but that access to the information would be mediated by an independent review panel.

Once the panel approves the request, Daiichi will anonymise the information to protect patient privacy, and will make requested analyses available in “a secure electronic environment”.

The Clinical Study Data Request website was spearheaded in 2013 by GlaxoSmithKline, which lists on the site 1,700 clinical trials dating back to the company's formation in 2000.

The site also has the backing of 12 other companies, including Eisai, Astellas, UCB, Boehringer Ingelheim and Lilly - the latter two promising to make records from the late 1990s available.

Since May 2013 the AllTrials transparency campaign says data have been made available via the Clinical Study Data Request website to over 80 research teams.

Furthering the site's credentials, a new independent review panel was appointed last week by the Wellcome Trust. The new five-member panel will be chaired by Professor Jeffrey Koplan, president for global health at Emory University and means both the panel and review process are completely independent from the trial sponsors offering to make data available.

Article by
Dominic Tyer

4th February 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Reynolds-MacKenzie

Reynolds-MacKenzie is the multi award-winning specialist public relations practice within OPEN Health; the first ever agency in the health communications...

Latest intelligence

Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...
Cost containment and the German market
The healthcare system’s budget limitations will face further pressure from challenges such as personalised medicine...

Infographics